FindTrial
Sign In

classification of gastric and gastro-esophageal cancers based on expression of immunohistochemical markers

Immunohistochemical sub-typing of gastric and gastro-esophageal junction tumors and its correlation with disease stage: a prospective descriptive study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/04/032945
Enrollment
50
Registered
2021-04-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C16- Malignant neoplasm of stomach

Interventions

None listed

Sponsors

IPSIT ILAHI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age > 18years 2) Biopsy proven primary adenocarcinoma of the gastric and gastro-esophageal junction 3) Willing to undergo staging investigations 4) Consenting to participate in the study

Exclusion criteria

Exclusion criteria: 1. Insufficient tissue sample for immuno-histochemical study 2. Prior anti-cancer treatment 3. History of prior malignancy

Design outcomes

Primary

MeasureTime frame
The prevalence of various immunohistochemical markers (EBV, MSI, TP53) in gastric and GE junction tumors in North Indian patientsTimepoint: At the time of diagnosis—

Secondary

MeasureTime frame
Correlation of immuno-histochemical based classification of gastric and GE junction tumors with disease stageTimepoint: At the time of diagnosis—

Countries

India

Contacts

Public ContactIPSIT ILAHI

ALL INDIA INSTITUTE OF MEDICAL SCIENCES, RISHIKESH

DR.PANKAJGARG@gmail.com9868708542

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026